Correction: System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma
Cheng Yan, Yandie Niu, Feng Li, Wei Zhao, Liukai Ma
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsFerroptosis and cancer prognosis · RNA modifications and cancer · Epigenetics and DNA Methylation
Correction: J Transl Med 20, 455 (2022)
10.1186/s12967-022-03632-z
Following publication of the original article [1], the authors reported inadvertent image misuses in Figure 8 and errors in the Figure Legend. Specifically, Figures 8E (EdU Assay – CFPAC-1), 8H (EdU Assay – PANC-1) and 8I (Transwell Assay – PANC-1) were misused.
The incorrect version of Figure 8 and Legend was:
Fig. 8. Knockdown of GSDMC inhibited PAAD cell proliferation and migration. A Western blot results showing the expression levels of indicated proteins in PANC-1 (left panel) or CFPAC-1 (right panel) cell line transfected with scrambled or two independent siRNA targeting GSDMC, respectively. B, C Cell viability was determined by CCK8 assay in the PANC-1 (B) and CFPAC-1 (C) cell lines transfected with either scrambled or two independent GSDMC siRNA targeting GSDMC, respectively. ***p < 0.001 by one-way ANOVA. D, F Colony formation assay of CFPAC-1 (D) and PANC-1 (F) cell lines with either scrambled or two independent siRNA targeting GSDMC, respectively. ***p < 0.001 by one-way ANOVA. E, H Edu assay to show the cell proliferation of PANC-1 (E) and CFPAC-1 (H) cell lines transfected with either scrambled or two independent siRNA targeting GSDMC, respectively. *p < 0.05 by one-way ANOVA. J, K Wound healing assay of PANC-1 (J) and CFPAC-1 (K) cell migration capability following transfected with scrambled or two independent siRNA targeting GSDMC, respectively. ***p < 0.001 by one-way ANOVA
The correct Figure 8 and Legend are:
Fig. 8. Knockdown of GSDMC inhibits PAAD cell proliferation and migration. A Western blot analysis showing GSDMC expression in PANC-1 (left) and CFPAC-1 (right) cells transfected with scrambled control or two independent siRNAs targeting GSDMC. B,** C** Cell viability of CFPAC-1 (B) and PANC-1 (C) cells was measured by CCK-8 assay. p < 0.001 by one-way ANOVA. D, F* Colony formation assays of CFPAC-1 (D) and PANC-1 (F) cells with or without GSDMC knockdown. p < 0.001 by one-way ANOVA. E, H* EdU assays showing reduced proliferation of CFPAC-1 (E) and PANC-1 (H) cells upon GSDMC knockdown. p < 0.05 by one-way ANOVA. G,* I** Transwell assays showing decreased migration in CFPAC-1 (G) and PANC-1 (I) cells following siRNA-mediated knockdown of GSDMC. p < 0.05 by one-way ANOVA. J,* K** Wound healing assays demonstrating reduced migration of CFPAC-1 (J) and PANC-1 (K) cells after GSDMC depletion. ***p < 0.001 by one-way ANOVA
The original article [1] has been updated.